The ambruticins and jerangolids – chemistry, biology and chemoenzymatic synthesis of potent antifungal drug candidates
Authors:
- 18 May 2020
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in Natural Product Reports
- Vol. 37 (10) , 1300-1315
Abstract
Covering: 1977 to 2020 The ambruticins and jerangolids are myxobacterial reduced polyketides, which are produced via highly unusual biosynthetic pathways containing a plethora of non-canonical enzymatic transformations. Since the discovery of the first congeners in the late 1970s, they have been in the focus of drug development due to their good antifungal activity and low toxicity in mammals, which result from interaction with an unusual innercellular target in fungi. Despite significant efforts, which have led to the development of various total syntheses, their structural complexity has yet avoided full exploitation of their pharmacological potential. This article summarises biological, total and semisynthetic as well as biosynthetic studies on both compounds. An outlook on the biosynthesis-based approaches to them and their derivatives is presented. Due to the structural and biosynthetic characteristics of the ambruticins and jerangolids, chemoenzymatic processes that make use of their biosynthetic pathway enzymes are particularly promising to gain efficient access to derivative libraries for structure activity relationship studies.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (HA 5841/2-1)
- Deutsche Forschungsgemeinschaft (HA 5841/4-1)
- FP7 People: Marie-Curie Actions (293430)
This publication has 73 references indexed in Scilit:
- A comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promiseChemical Society Reviews, 2020
- Perquinolines A–C: Unprecedented Bacterial Tetrahydroisoquinolines Involving an Intriguing BiosynthesisAngewandte Chemie International Edition, 2019
- Structure, Total Synthesis, and Biosynthesis of Chloromyxamides: Myxobacterial Tetrapeptides Featuring an Uncommon 6‐Chloromethyl‐5‐methoxypipecolic Acid Building BlockAngewandte Chemie International Edition, 2018
- Natural products from myxobacteria: novel metabolites and bioactivitiesNatural Product Reports, 2016
- Natural Products as Sources of New Drugs from 1981 to 2014Journal of Natural Products, 2016
- In vitro reconstitution of α-pyrone ring formation in myxopyronin biosynthesisChemical Science, 2015
- The re-emergence of natural products for drug discovery in the genomics eraNature Reviews Drug Discovery, 2015
- Antifungal Drug Discovery: The Process and OutcomesFuture Microbiology, 2014
- Myxobacterial secondary metabolites: bioactivities and modes-of-actionNatural Product Reports, 2010
- Natural Products as a Foundation for Drug DiscoveryCurrent Protocols in Pharmacology, 2009